Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitors in Osteoporosis Management

摘要: OBJECTIVE:To evaluate the use and potential benefit of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) in management osteoporosis.DATA SOURCES:Clinical literature accessed through MEDLINE (1994–May 2001) using key search terms HMG-CoA inhibitors, statins, osteoporosis, fractures.DATA SYNTHESIS:Osteoporosis is most common bone disease, affecting millions people worldwide leading to significant morbidity high expenditures, especially when it not adequately managed. Recent data have documented a association between statin improvement fracture risk profile. Therefore, an evaluation studies investigating effect on was conducted.CONCLUSIONS:Observational suggest reduction risk. However, large randomized controlled are needed confirm this association.